Bempikibart Cut Hair Loss Scores 35.3% in Alopecia Areata Trial
Q32 Bio's bempikibart cut SALT hair-loss scores by 35.3 percent at week 36, with 40 percent of severe alopecia areata patients reaching SALT-20 — even after failing JAK inhibitors.
Updated
The takeaway
- Bempikibart reduced average SALT scores by 35.3 percent at week 36 in the SIGNAL-AA phase 2a trial's Part B, enrolling 33 patients with 50-100 percent scalp hair loss.
- Forty percent of patients reached a SALT-20 response (80 percent or more scalp hair coverage); more than a third had previously failed oral JAK inhibitors.
- Bempikibart holds FDA Fast Track designation granted in March 2025; Q32 Bio plans a registration-directed program in the first half of 2027.
Bempikibart, an experimental antibody from Q32 Bio, reduced scalp hair loss scores by an average of 35.3 percent over 36 weeks in patients with severe alopecia areata — including many who had already failed on JAK inhibitors, according to results the company reported from Part B of its SIGNAL-AA phase 2a trial, as covered by Dermatology Times.
The trial enrolled 33 patients with severe or very severe alopecia areata, defined as 50 to 100 percent scalp hair loss, with a current episode lasting no more than four years. Enrollment ran higher than planned because patient demand pushed it past the original target. Patients received weekly injections of bempikibart for four weeks, then injections every other week through week 36.
At week 36, participants' Severity of Alopecia Tool (SALT) scores — the standard measure of scalp hair loss — fell by an average of 35.3 percent from baseline. Forty percent of patients achieved a SALT-20 response, meaning 80 percent or more scalp hair coverage.
The standout finding concerns JAK inhibitors, one of today's most common alopecia areata treatments. More than a third of trial participants had already tried an oral JAK inhibitor without lasting success. Bempikibart still worked for many of them.
Alopecia areata follows a frustrating pattern: hair falls out, sometimes grows back, then falls out again, often with no clear answers for people who have exhausted standard options.
Arash Mostaghimi, MD, a Boston dermatologist and associate professor of dermatology at Harvard Medical School, said the findings reinforce bempikibart's potential as an alternative to JAK inhibitors. "The robust efficacy data in a population that includes JAK inhibitor-experienced patients, combined with a differentiated safety profile, demonstrate the potential for bempikibart to be a first-line treatment for alopecia areata," Dr. Mostaghimi said. "For patients and prescribers seeking an effective and safe alternative to JAK inhibitors, these findings are encouraging and merit further clinical advancement."
The safety data supports his read. The most common side effect was mild injection site reactions, which mostly resolved within a day. No serious adverse events occurred during the trial.
Bempikibart already holds FDA Fast Track designation, granted in March 2025. Q32 Bio says the 36-week data supports moving toward a registration-directed program in the first half of 2027.
The drug is not approved yet, and larger trials lie ahead. For people whose alopecia areata has not responded to existing treatments, the results are reason for cautious optimism — and one more reason to discuss hair loss treatment history with a dermatologist as new therapies move through the pipeline.
Source: NewBeauty; Source: dermatologytimes.com
Amara Osei
Show full bio
Staff writer covering media and advertising at Eurasian Beauty Journal.
